EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs-Reference-Cited by-同舟云学术

EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

Published:2015-07-23 Issue:23 Volume:21 Page:5305-5313
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Kobayashi Yoshihisa,Togashi Yosuke,Yatabe Yasushi,Mizuuchi Hiroshi,Jangchul Park,Kondo Chiaki,Shimoji Masaki,Sato Katsuaki,Suda Kenichi,Tomizawa Kenji,Takemoto Toshiki,Hida Toyoaki,Nishio Kazuto,Mitsudomi Tetsuya

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 171 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated multi-omics profiling reveals a clinically relevant molecular feature and potential therapeutic target on phyllodes tumors of breast;Translational Oncology;2024-08

2. Conformational Transitions in EGFR Protein Tyrosine Kinase Domain and Their Modulation by Mutants;Proceedings of the National Academy of Sciences, India Section B: Biological Sciences;2024-06-14

3. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO);ESMO Open;2024-06

4. Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report;Frontiers in Oncology;2024-05-06

5. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC;Clinical Cancer Research;2024-04-05